Cabgolin
Cabgolin Price range: $ 134,00 through $ 356,00
Back to products
Calcium Carbonate
Calcium Carbonate Price range: $ 41,00 through $ 535,00

Calan

Price range: $ 46,00 through $ 242,00

Calan is a highly effective calcium channel blocker designed to manage a variety of cardiovascular conditions by relaxing blood vessels and improving circulation. It is primarily used to treat hypertension, helping to lower high blood pressure and reduce the overall strain on the heart. This medication is also indicated for the management of chronic stable angina, effectively preventing chest pain during physical activity. Additionally, Calan helps regulate certain heart rhythm disorders, such as supraventricular tachycardia, to ensure a steady and healthy heartbeat. By enhancing cardiac efficiency, this treatment provides reliable support for long-term cardiovascular stability and wellness.

Active substance: Verapamil
SKU: Calan Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Calan belongs to a class of medications known as non-dihydropyridine calcium channel blockers. It is an FDA-approved prescription drug primarily used to manage high blood pressure, relieve chest pain, and control certain heart rhythm disorders.

Treatment with Calan requires individual medical evaluation and a prescription from a licensed healthcare provider, as dosing and administration must be tailored to specific cardiovascular conditions.

Property Details
Active ingredient Verapamil hydrochloride
Therapeutic class Calcium channel blocker (phenylalkylamine)
Dosage form Oral tablet
Prescription status Prescription (Rx) only
Primary purpose Management of hypertension, angina pectoris, and cardiac arrhythmias
Route of administration Oral

How the drug works

Calan inhibits the transmembrane influx of calcium ions into cardiac muscle cells and vascular smooth muscle cells. By selectively blocking L-type calcium channels, the active substance verapamil dilates coronary arteries and peripheral arterioles, which reduces systemic vascular resistance and lowers arterial blood pressure. In addition to vascular effects, Calan slows electrical conduction through the atrioventricular (AV) node in the heart. This action prolongs the refractory period within the AV node, helping to slow and normalize rapid heart rates. The reduction in vascular resistance and heart rate ultimately decreases myocardial oxygen consumption, rendering the drug effective in preventing angina attacks.

Main uses

Calan is indicated for the treatment of essential hypertension to control elevated blood pressure and lower the risk of cardiovascular events. It is also FDA-approved for the management of angina pectoris, including vasospastic (Prinzmetal’s) angina, chronic stable angina, and unstable angina. Furthermore, Calan is prescribed for digitalis-controlled rate control in patients with chronic atrial flutter or atrial fibrillation, as well as for the prophylaxis of recurrent paroxysmal supraventricular tachycardia (PSVT). Any application outside these approved labeling parameters, such as cluster headache prevention, represents an off-label use that must be explicitly evaluated and monitored by a prescribing physician.

Dosing schedule

The dosage of Calan must be individualized based on the patient’s specific cardiovascular condition, renal function, and clinical response. Oral tablets are typically administered with water, and taking them with food can help minimize gastrointestinal discomfort. Physicians generally initiate therapy at lower doses and gradually titrate upward to evaluate efficacy and tolerability. Dosage adjustments are mandatory for patients with hepatic impairment, renal dysfunction, or for elderly individuals who clear the drug more slowly. Patients must strictly follow the dosing schedule provided by their doctor and refrain from doubling doses or abruptly altering their regimen.

What happens in the body

Following oral administration, more than 90% of verapamil is rapidly absorbed from the gastrointestinal tract. However, due to extensive first-pass hepatic metabolism, its absolute systemic bioavailability ranges between 20% and 35%. The drug is heavily bound to plasma proteins, approximately 90%. Metabolism occurs primarily in the liver via the cytochrome P450 enzyme system, predominantly through the CYP3A4 pathway, producing several metabolites including norverapamil, which retains minimal pharmacological activity. The elimination half-life of immediate-release verapamil ranges from 2.8 to 7.4 hours after a single oral dose, but this may extend to 4.5 to 12 hours during chronic maintenance therapy. Excretion occurs mainly through the kidneys, with roughly 70% of the dose eliminated in urine as metabolites.

Compatibility with other medicines

Calan is involved in numerous clinically significant drug interactions due to its dual role as a substrate and inhibitor of the CYP3A4 enzyme and P-glycoprotein transporter. Co-administration with beta-blockers, such as atenolol or metoprolol, can cause additive negative effects on cardiac conduction and contractility, potentially resulting in severe bradycardia or heart block. Verapamil increases plasma concentrations of digoxin, carbamazepine, lithium, and certain HMG-CoA reductase inhibitors like simvastatin and lovastatin, raising the risk of toxicity. Concomitant use with other antihypertensive agents can lead to excessive blood pressure reduction. Patients must disclose all prescription medications, over-the-counter products, and herbal supplements to their healthcare provider.

Adverse reactions

The side effect profile of Calan relates directly to its pharmacological action on smooth muscle relaxation and cardiac conduction. Constipation is the most frequently observed adverse reaction, occurring because verapamil inhibits smooth muscle motility in the gastrointestinal tract. Other common side effects include dizziness, headache, peripheral edema (swelling of the ankles or feet), nausea, fatigue, and low blood pressure (hypotension). Less common but serious adverse events involve sinus bradycardia, second-degree or third-degree AV block, and worsening heart failure. Mild side effects often diminish over time, but persistent or bothersome symptoms require clinical re-evaluation.

Important precautions

Calan is contraindicated in patients with severe left ventricular dysfunction, cardiogenic shock, severe hypotension, sick sinus syndrome (unless a functioning artificial pacemaker is present), and second- or third-degree AV block. Caution is required when prescribing Calan to individuals with impaired liver or kidney function, as diminished clearance leads to drug accumulation and heightened toxicity risk. Patients with neuromuscular transmission disorders, such as myasthenia gravis, may experience worsening muscle weakness. Regular clinical evaluation, including blood pressure readings and electrocardiographic (ECG) monitoring, is essential during initial dose titration and ongoing maintenance.

If you skip a dose

If a dose of Calan is missed, it should be taken as soon as remembered on that day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Patients should never take two doses at the same time or take extra medication to compensate for a missed dose. Maintaining consistent plasma levels is crucial for stable blood pressure control and cardiac rhythm management.

What to avoid while taking it

Patients taking Calan must avoid consuming grapefruit or grapefruit juice. Grapefruit contains compounds that inhibit intestinal CYP3A4 enzymes, significantly increasing verapamil blood levels and escalating the risk of severe side effects such as hypotension and bradycardia. Alcohol consumption should also be limited or avoided; verapamil can inhibit alcohol metabolism, leading to elevated blood alcohol concentrations and prolonged intoxication. Additionally, combining alcohol with blood pressure medications increases the likelihood of dizziness and fainting.

Special populations

In pregnant women, Calan should be used only if the potential therapeutic benefit justifies the potential risk to the fetus, as adequate and well-controlled studies in pregnant humans are limited. Verapamil crosses the placenta and is excreted into human breast milk in small quantities; nursing mothers should consult their provider to weigh the risks and benefits of continuing treatment while breastfeeding. Elderly patients often demonstrate reduced drug clearance and increased sensitivity to verapamil, resulting in a higher incidence of constipation, hypotension, and bradycardia. Pediatric safety and effectiveness vary by specific indication and require specialized pediatric cardiac oversight.

Red flags

Immediate medical attention is necessary if signs of a severe adverse event or allergic reaction develop while taking Calan. Urgent emergency care should be sought if any of the following occur:

  • Shortness of breath or difficulty breathing
  • Unexplained, rapid swelling of the feet, ankles, or lower legs
  • Chest pain, severe dizziness, lightheadedness, or fainting (syncope)
  • An abnormally slow or irregular heartbeat
  • Signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, accompanied by rash or hives

Common questions

Can Calan cause constipation, and how can it be managed?

Yes, constipation is one of the most frequent side effects associated with Calan because the medication relaxes smooth muscle tissue within the digestive tract. Patients experiencing mild constipation are generally advised to maintain adequate fluid intake, increase dietary fiber, and engage in light physical activity as tolerated. If constipation persists or becomes uncomfortable, patients should consult their doctor for safe, appropriate management options.

Why must grapefruit juice be avoided while taking Calan?

Grapefruit juice inhibits the CYP3A4 liver and intestinal enzyme responsible for metabolizing verapamil. Inhibiting this metabolic pathway causes verapamil concentrations in the bloodstream to rise significantly above expected levels. Higher drug levels increase the risk of pronounced low blood pressure, severe slowing of the heart rate, and other toxic effects.

What happens if Calan is discontinued abruptly?

Abruptly stopping Calan can cause a sudden rebound in blood pressure or a sharp increase in the frequency and severity of angina attacks. If the medication needs to be discontinued, healthcare providers typically advise reducing the dosage gradually over time under close clinical supervision to protect cardiovascular stability.

Is it safe to perform activities like driving after starting Calan?

Calan can cause dizziness, drowsiness, or lightheadedness, particularly when treatment is first initiated or after a dose increase. Patients should observe how their body responds to the drug before driving, operating machinery, or performing tasks that require full mental alertness and coordination.

How does Calan interact with beta-blocker medications?

Combining Calan with beta-blockers exerts an additive slowing effect on the heart’s electrical conduction system and reduces heart muscle contraction strength. This combination increases the risk of severe bradycardia, AV block, and heart failure. When co-administration is necessary, careful monitoring by a physician in a setting such as an outpatient clinic in Chicago or local cardiology office is mandatory.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

80mg

,

120mg

,

240mg

Package

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία